Bruker Corp 6.375% PRF PERPETUAL USD 0.01 - Ser A (BRUKV) Stock Price | Live Quotes & Charts | GREY
This page provides live quotes and charts for Bruker Corp's 6.375% PRF PERPETUAL USD 0.01 - Ser A (BRUKV) stock, listed as GREY. It shows the current price as $250.50 with 0.00% change, indicating delayed prices and offering an option to get real-time quotes. The article also mentions the absence of analyst ratings or earnings information for this specific stock.
BRKR SEC Filings - Bruker Corp 10-K, 10-Q, 8-K Forms
This page provides access to Bruker Corp's (BRKR) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms, enhanced with AI-powered summaries. The filings offer detailed insights into the company's financial performance, operating conditions, and significant corporate events. Recent filings cover T. Rowe Price's stake, insider stock sales, Bruker's 2025 financial results and 2026 guidance, and executive stock transactions.
BRKR SEC Filings - Bruker Corp 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Bruker Corporation (BRKR) SEC filings, including 10-K, 10-Q, 8-K, and Form 4 documents. It offers AI-powered summaries of complex sections to help investors understand financial conditions, operating performance, and material corporate events. Recent filings detail insider transactions, executive RSU grants, and tax-related share withholdings by key personnel like the CEO and CFO.
Thierry L. Bernard appointed to Bruker board as QIAGEN CEO set to step down
Bruker has appointed Thierry L. Bernard to its Board of Directors, effective April 1, 2026, as an expansion of the board. Bernard is currently the CEO and Managing Director of QIAGEN and has held various leadership roles in the life sciences industry. His committee assignments at Bruker will be disclosed in a future SEC filing.
Bruker Announces Appointment of Thierry Bernard to its Board of Directors
Bruker Corporation has announced the appointment of Thierry L. Bernard to its Board of Directors, effective April 1, 2026. Mr. Bernard brings extensive leadership experience from the life-science tools and diagnostics industry, including his current role as CEO of QIAGEN N.V. The company aims to leverage his expertise to further develop its leadership in life-science research, biopharma, and diagnostic solutions.
BRKR Stock News Today | Earnings, Events & Price Alerts
This page provides a comprehensive overview of recent news, events, and price alerts for Bruker Corporation (BRKR). Key updates include patent revocations, new board appointments, financial results, and analyst insights, offering a summary of the company's activities and market performance.
Bruker, Seer Each Claim Partial Win in US Patent Board Ruling
The US Patent and Trademark Office's Patent Trial and Appeal Board has issued rulings in an inter partes review process involving Bruker and Seer. Both companies are claiming partial victories, indicating a mixed outcome in the patent dispute. The specific details of the patent claims and the board's decisions are not yet fully elaborated.
Guggenheim Maintains Bruker Corp(BRKR.US) With Buy Rating, Cuts Target Price to $50
Guggenheim has reiterated its Buy rating for Bruker Corp (BRKR.US) but has lowered its target price for the stock to $50. This adjustment reflects a revised valuation while still maintaining a positive outlook on the company's prospects.
Bruker Corp (BRKR) Stock Price Quote Today & Current Price Chart
This article provides a stock price quote and current price chart for Bruker Corp (BRKR). It is presented on a platform for online trading with a smart investment app.
Vanguard disaggregates holdings; reports 0 shares in Bruker (NYSE: BRKR)
The Vanguard Group filed an Amendment No. 8 to a Schedule 13G/A, reporting zero beneficial ownership of Bruker Corp (BRKR) common stock. This change follows an internal realignment effective January 12, 2026, where certain Vanguard subsidiaries or business divisions began reporting ownership separately under SEC Release No. 34-39538. The filing indicates a procedural change in reporting and does not affect Bruker's capitalization or share structure.
Will Bruker (BRKR) be Able to Rebound?
Artisan Small Cap Fund's Q4 2025 investor letter highlighted Bruker Corporation (NASDAQ:BRKR), a leading provider of scientific instruments. Despite recent stock declines and headwinds from research funding and the Chinese market, Artisan increased its position, anticipating a rebound in 2026 due to product innovation and strategic acquisitions. However, Bruker is not among the 40 most popular stocks with hedge funds, and some AI stocks are considered to have greater upside potential.
Bruker (NASDAQ: BRKR) EVP Mark Munch exercises options and sells 2,000 shares
Bruker (NASDAQ: BRKR) Executive Vice President Mark Munch recently exercised stock options for 2,000 shares at $22.19 per share and subsequently sold those 2,000 shares at $35.44 per share. These transactions, executed under a pre-arranged Rule 10b5-1 trading plan, resulted in Munch directly holding 128,443 shares of common stock. The filing indicates this was a planned liquidity event rather than an opportunistic trade.
Bruker Corp Stock (ISIN: US1167941087) Faces Rising Short Interest Amid Investor Scrutiny
Bruker Corp (ISIN: US1167941087) is experiencing increased short interest, reaching 9.39% of its public float, reflecting investor skepticism regarding its growth in a high-interest-rate environment. Despite this, a new $1.11 million investment by Callodine Capital Management LP suggests a mixed sentiment. The company's resilience is supported by its installed base and recurring revenue from consumables and services, though risks include biopharma R&D cuts and forex volatility.
Mark R Munch reports multiple share sales (BRKR) under Rule 144
Mark R Munch, an insider at Bruker Corp (BRKR), has reported multiple sales of common shares under Rule 144, including transactions on January 5, 12, and 15, 2026, and February 13, 2026. The largest disposition was 33,843 shares for $1,680,704 on January 5, 2026. Additionally, the filing details an exercise of a stock option for 2,000 shares on March 13, 2026, paid in cash, handled by Morgan Stanley Smith Barney LLC.
Bruker Corp. Experiences Revision in Stock Evaluation Amid Market Dynamics and Performance Challenges
Bruker Corp., a small-cap pharmaceutical and biotechnology company, has seen significant stock fluctuations and underperformed the S&P 500 over the past year and three years. Technical indicators show mixed signals, with bearish trends in MACD, Bollinger Bands, and Dow Theory on a weekly basis, despite a mildly bullish daily outlook from moving averages. The company's returns of -22.04% over one year and -51.39% over three years highlight challenges in keeping pace with broader market trends.
Bruker Corporation $BRKR Position Increased by Ceredex Value Advisors LLC
Ceredex Value Advisors LLC significantly increased its stake in Bruker Corporation (NASDAQ:BRKR) by 131.5% in Q3, bringing its holdings to 496,000 shares worth over $16 million. While insiders own a substantial portion of the company, a VP recently sold 2,000 shares. Analysts hold a mixed view, with a consensus "Hold" rating, after the company missed quarterly EPS estimates but exceeded revenue expectations and provided FY2026 guidance.
Is Bruker (BRKR) Quietly Recasting Its Competitive Moat With Spatial Biology And Proteomics Upgrades?
Bruker (BRKR) recently closed a significant shelf registration and introduced upgrades to its mass spectrometry and spatial biology platforms, including the new CellScape XR proteomics system. These advancements, coupled with collaborations in oncology and spatial biology, aim to expand Bruker's role in high-throughput research, supporting its long-term strategy for revenue growth and profitability despite current market headwinds. The company's narrative projects significant revenue and earnings growth by 2028, with a fair value indicating a potential 30% upside.
RSI Alert: Bruker (BRKR) Now Oversold
Bruker Corp (BRKR) shares have entered oversold territory with an RSI reading of 29.5, below the 30-point threshold. This technical indicator suggests that the recent heavy selling might be concluding, potentially offering a buying opportunity for bullish investors. The stock's current price of $36.68 is well above its 52-week low of $28.53, though significantly below its 52-week high of $56.22.
Research Tools & Consumables Stocks Q4 In Review: Bruker (NASDAQ:BRKR) Vs Peers
The article reviews the Q4 performance of Bruker (NASDAQ:BRKR) and other research tools & consumables stocks. It highlights the sector's reliance on recurring revenue, strong customer loyalty, and exposure to research and clinical markets, while also noting challenges such as high R&D investment and pricing pressures. Bruker reported flat revenues and exceeded analyst expectations for the quarter, but its stock declined due to a significant miss on EPS estimates.
Artisan Partners Limited Partnership Invests $13.69 Million in Bruker Corporation $BRKR
Artisan Partners Limited Partnership has initiated a new position in Bruker Corporation (NASDAQ:BRKR) by purchasing 421,201 shares valued at approximately $13.69 million, representing 0.28% of the company. This investment comes as Bruker reported a quarterly EPS of $0.59, missing the consensus, and set its FY2026 guidance below analyst expectations. Insider trading activity included VP Mark Munch selling 7,000 shares for $385,000, while institutional investors hold 79.52% of the stock.
Bruker Corp. Experiences Revision in Stock Evaluation Amid Market Volatility
Bruker Corp., a small-cap pharmaceuticals and biotechnology company, is currently priced at $41.02 and has experienced significant stock price volatility over the past year. The stock has declined by 18.77% in the last year and 40.89% over three years, underperforming the S&P 500 significantly. Technical indicators show a mixed performance, with mildly bearish trends on some longer-term metrics and mildly bullish on daily moving averages.
BRKR Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a comprehensive financial overview of Bruker Corp (BRKR), detailing its income statement, balance sheet, cash flow, and key financial ratios through fiscal year 2025. It highlights a decline in revenue and net income, alongside concerns about profitability, cash flow, and interest coverage. The company's financial health score is rated as "weak," with moderate financial risk indicated by its Altman Z-Score.
Bruker (BRKR): Buy, Sell, or Hold Post Q4 Earnings?
This article analyzes Bruker (BRKR) post-Q4 earnings, recommending caution despite recent stock outperformance. The author highlights concerns about stagnating organic revenue, shrinking adjusted operating margins, and declining return on invested capital as reasons not to invest. The article concludes that while the current valuation is fair, better investment opportunities exist elsewhere.
Bruker Corporation (NASDAQ:BRKR) Given Average Rating of "Hold" by Brokerages
Bruker Corporation (NASDAQ:BRKR) has received an average rating of "Hold" from fifteen brokerages, with a consensus one-year price target of $50.38. This comes after the company reported Q4 EPS of $0.59, missing estimates, although revenue slightly beat expectations. Bruker also provided FY2026 guidance with EPS lower than analyst forecasts, while insiders and institutional investors hold significant stakes in the company.
Bruker Accelerates the Future of Diagnostic and Prognostic Spatial Proteomics With the Launch of CellScape XR
Bruker Corporation launched CellScape XR, a new spatial proteomics platform designed to enhance diagnostic and prognostic assays by offering superior quantitative performance, robustness, and flexibility. This platform aims to overcome limitations in translational research by enabling high-throughput, reproducible spatial proteomics at a scale suitable for clinical applications. CellScape XR supports the entire lifecycle of spatial proteomics, from discovery to clinical assay development, accelerating the creation of next-generation diagnostics.
New Bruker tool targets 3,000-patient tumor study in spatial proteomics
Bruker has launched CellScape XR, a new spatial proteomics platform designed to accelerate diagnostic and prognostic assays. This platform offers enhanced quantitative performance, robustness, and flexibility, addressing the need for high-throughput, reproducible spatial proteomics in clinical translation. The University Hospital Schleswig-Holstein is already using the CellScape platform for a large tumor study, with plans to expand analysis to 3,000 patient samples.
Reasons Why Bruker Corporation (BRKR) Appears So Attractive
Bruker Corporation (BRKR) is identified as one of the top life sciences stocks, despite recent price target reductions by Jefferies and BofA analysts. Analysts maintain a "Buy" rating, anticipating improvements and a strong second-half recovery in 2026, even though Q4 2025 performance was soft. The company specializes in high-performance scientific instruments and analytical solutions across multiple segments.
Reasons Why Bruker Corporation (BRKR) Appears So Attractive
Bruker Corporation (NASDAQ: BRKR) is highlighted as one of the top 10 life sciences stocks according to hedge funds, despite recent price target reductions from Jefferies and BofA analysts. Both analysts maintained a "Buy" rating, citing potential for recovery in 2026, driven by improving conditions and strong second-half performance. The company specializes in scientific instruments and analytical solutions across various segments.
BRKRP Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of Bruker Corp (BRKRP), including its income statement, balance sheet, cash flow statement, and key financial ratios. For fiscal year 2024, the company reported $3.4 billion in revenue, a 13.6% increase year-over-year, but experienced a significant decrease in net income and free cash flow. Bruker Corp's financial profile scores 44 out of 100, indicating moderate financial health with strong leverage, but lower scores in cash flow and returns.
Inside Bruker and Noetik’s push toward 1B mapped human cells
Bruker Spatial Biology announced an expanded collaboration with Noetik Inc. to advance tissue foundational models using spatial molecular imaging (SMI). Noetik leverages Bruker's CosMx SMI platform to generate extensive spatial transcriptomic and multiomic datasets, aiming to scale toward one billion spatially resolved human cells to train advanced AI models for oncology and beyond. This partnership seeks to transform drug discovery and therapeutic applications by enabling complex genome-wide simulations of human cellular and tissue biology.
Bruker taps AI to map disease proteins for new drug targets
Bruker has introduced new advancements in its Functional Proteomics 2.0 workflows for the timsOmni mass spectrometer, focusing on proteoform and PTM-resolved peptide variant analysis to deepen insights into disease biology. The company's updated software, including Bruker ProteoScape, OmniScape, and GlycoScape, leverages AI-enhanced de novo peptide sequencing and a novel OmniWave algorithm to improve identification of disease-driving proteoforms and enhance glycopeptide characterization. These developments aim to provide more detailed biological, disease, and drug discovery insights by moving beyond traditional protein lists.
Bruker Announces Major Advancements at AGBT to Enable Complete High-Fidelity Spatial Biology Across the Biological Spectrum – Company Announcement
Bruker Corporation announced significant advancements in its spatial biology portfolio at the 2026 AGBT General Meeting, including the launch of the new CellScape XR spatial proteomics platform, the PaintScape 3D genome visualization platform now open for pre-orders, and an expanded CosMx mouse whole transcriptome panel. These innovations aim to provide comprehensive multiomic capabilities across DNA, RNA, and protein, enhancing scientific research from discovery to translational studies. Bruker also revealed plans for high-plex spatial miRNA and T-Cell Receptor assays, and introduced AI-ready analysis features for its AtoMx Spatial Informatics Platform, alongside a new collaboration with the University of Glasgow to study pancreatic cancer.
Inside Bruker’s new tools to map cancer and cells in 3D space
Bruker Corporation unveiled significant advancements in its spatial biology portfolio at the 2026 Advances in Genome Biology and Technology (AGBT) General Meeting, introducing new platforms like CellScape XR for spatial proteomics and PaintScape for 3D genome visualization. The company is expanding capabilities for its CosMx Spatial Molecular Imager to include mouse whole transcriptome, miRNA, and TCR assays, alongside enhancements to its AtoMx Spatial Informatics Platform for AI-ready data. These innovations aim to provide researchers with comprehensive tools for high-fidelity spatial analysis, from discovery to translational research, exemplified by a major collaboration with the University of Glasgow on pancreatic cancer.
Bruker Corp (NASDAQ: BRKR) director granted 4,520 restricted stock units
Bruker Corp director Hermann Fritz Requardt was granted 4,520 restricted stock units (RSUs) on February 15, 2026, as equity compensation with a price of $0.00 per share. These RSUs will vest in a single installment on February 15, 2027, and will automatically convert into common stock. Following this grant, Requardt directly holds 30,965 shares of Bruker Corp common stock.
Bruker (BRKR) director Cynthia Friend awarded 4,520 RSUs vesting 2027
Bruker (BRKR) director Cynthia M. Friend was awarded 4,520 Restricted Stock Units (RSUs) on February 15, 2026. These RSUs will vest in a single installment on February 15, 2027, and will convert into an equal number of Common Stock shares. Following this grant, Ms. Friend directly holds 22,536 shares of Bruker Common Stock, with no cash payment made for the RSU award.
Bruker (BRKR) executive exercises options and sells 2,000 shares
Mark Munch, Executive Vice President and President of Bruker Nano Inc., exercised stock options for 2,000 Bruker (BRKR) shares at $22.19 per share on February 13, 2026. Following this, he sold 2,000 common shares at $36.94 per share under a Rule 10b5-1 trading plan. After these transactions, Munch directly owns 128,443 shares of Bruker common stock and holds 14,000 stock options.
Nasdaq Analyst Becomes Optimistic; Check Out the Top 5 Upgrades for Thursday
Several Wall Street analysts have upgraded their ratings for various companies, including AVITA Medical, Agios Pharmaceuticals, Nasdaq, and Marsh & McLennan. AVITA Medical was upgraded from Sell to Neutral by BTIG, while Agios Pharmaceuticals was upgraded from Market Perform to Outperform by Leerink Partners. Morgan Stanley upgraded Nasdaq to Overweight, and Barclays upgraded Marsh & McLennan to Overweight.
The Top 5 Analyst Questions From Bruker's Q4 Earnings Call
Bruker (BRKR) faced a challenging Q4 2025 with ongoing weakness in U.S. academic and government funding, tariff pressures, and unfavorable currency movements, leading to an EPS miss though revenue beat estimates. Analysts questioned management on the sustainability of cost reductions, confidence in margin expansion, growth assumptions across markets, backlog trends, and Q1 revenue expectations, to which the company provided detailed responses outlining future strategies and market outlook. Key catalysts for upcoming quarters include monitoring cost-saving realization, sustained order momentum, and stabilization in U.S. funding.
3D Protein Structure Analysis Market Report 2026 Featuring
The global 3D protein structure analysis market is projected to grow from $3.4 billion in 2025 to $5.3 billion by 2030, driven by its critical role in drug development, personalized medicine, and biotech research. Key growth catalysts include advancements in AI and cloud computing, increased R&D investment, and strategic expansion in the Asia-Pacific region. The market is segmented by instruments, consumables, and software, with North America currently dominating and Asia-Pacific showing rapid growth.
Bruker Corp (BRKR) Shares Up 3.12% on Feb 17
Bruker Corp (BRKR) shares rose 3.12% on February 17, closing at $37.65, putting it 33.03% below its 52-week high and 31.97% above its 52-week low. Wall Street analysts predict an average one-year price target of $48.95, suggesting a 30.02% upside, and an "Outperform" recommendation. GuruFocus estimates a fair value of $73.38, indicating a potential 94.9% upside.
Bruker's Q4 Earnings Lag Estimates, Margins Contract, Stock Down
Bruker Corporation (BRKR) reported Q4 2025 adjusted earnings that missed analyst estimates by 9.2%, falling 22.4% year over year, despite revenues slightly beating expectations. The company experienced contracting gross and operating margins due to lower volume, unfavorable mix, tariffs, and currency headwinds. Bruker provided 2026 guidance, projecting revenue growth of 4% to 5% and adjusted EPS growth of 15% to 17%.
US$48.43: That's What Analysts Think Bruker Corporation (NASDAQ:BRKR) Is Worth After Its Latest Results
Following Bruker Corporation's latest annual results, analysts have updated their forecasts, leading to a considerable shift in sentiment. Despite revenues aligning with expectations at US$3.4 billion, projected losses per share for 2026 have increased significantly to US$2.15, overturning previous profit predictions. Consequently, the consensus price target has been lowered by 11% to US$48.43, reflecting concerns over ongoing losses and a slower projected revenue growth rate compared to the industry.
A Quick Look at Today's Ratings for Bruker Corp(BRKR.US), With a Forecast Between $35 to $49
Major Wall Street analysts have updated their ratings for Bruker Corp (BRKR.US) on February 14th, with price targets ranging from $35 to $49. Goldman Sachs initiated coverage with a sell rating at $35, while BofA Securities maintained a buy rating, adjusting its target to $49. Other analysts from Citi, UBS, and TD Cowen maintained hold ratings with revised or maintained target prices.
Bruker (BRKR) Price Target Lowered by Citigroup, Rating Maintained | BRKR Stock News
Citigroup analyst Patrick Donnelly has lowered the price target for Bruker (BRKR) from $53.00 to $40.00, while maintaining a 'Neutral' rating on the stock. Despite this reduction, other analysts have recently raised their price targets for Bruker, and the average target price from 16 analysts suggests a 43.97% upside from its current price. GuruFocus estimates a one-year fair value of $74.37 for BRKR, indicating a potential upside of 104.37%.
These Analysts Cut Their Forecasts On Bruker Following Q4 Results
Bruker (NASDAQ: BRKR) reported mixed Q4 financial results, with earnings missing analyst estimates but sales exceeding expectations. Following the report, two analysts, Luke Sergott from Barclays and Dan Brennan from TD Cowen, lowered their price targets on Bruker shares. The company provided its outlook for FY2026 adjusted EPS and sales, with the sales forecast beating current estimates.
Analysts Have Been Trimming Their Bruker Corporation (NASDAQ:BRKR) Price Target After Its Latest Report
Bruker Corporation (NASDAQ:BRKR) saw its stock drop 13% after its latest annual report, despite revenues aligning with analyst predictions. Although revenues are expected to increase slightly in 2026, analysts have shifted from forecasting a profit to a loss, leading to an 11% reduction in the consensus price target. This change reflects increased pessimism about the company's intrinsic value, with expected revenue growth slowing compared to historical performance and the broader industry.
Bruker Corporation (NASDAQ:BRKR) Q4 2025 Earnings Call Transcript
Bruker Corporation (NASDAQ:BRKR) reported its Q4 2025 earnings, with revenues ahead of expectations but missing EPS estimates due to various headwinds including tariffs and currency. The company provided a full-year 2026 financial outlook, anticipating 4% to 5% reported revenue growth and significant non-GAAP operating profit margin expansion. Bruker expects a return to organic revenue growth in Q2 2026 after a projected decline in Q1, driven by improving market conditions, cost-saving initiatives, and strong order momentum in several end markets.
A Quick Look at Today's Ratings for Bruker Corp(BRKR.US), With a Forecast Between $40 to $53
Several Wall Street analysts updated their ratings for Bruker Corp (BRKR.US) on February 13, 2026, setting price targets between $40 and $53. Analyst ratings include one hold and three buy recommendations, with adjusted target prices reflecting a range of expert opinions on the stock's future performance.
BRUKER ($BRKR) Releases Q4 2025 Earnings
Bruker ($BRKR) reported its Q4 2025 earnings, missing analyst estimates for both earnings per share and revenue. The company reported earnings of $0.59 per share against an estimated $0.66, and revenue of $977.2 million compared to an estimated $980.05 million. The article also provides details on insider trading activity, hedge fund movements, government contracts, and analyst ratings for BRKR.
Bruker Shares Tumble on Q4 Earnings Miss and Weaker Margins Despite 2026 Growth Outlook
Bruker Corporation's shares fell sharply after missing Q4 earnings expectations and reporting weaker margins. The company's Q4 revenues were flat year-over-year, and adjusted EPS declined, attributed to cost pressures and volume weakness. Despite a challenging 2025, Bruker provided 2026 guidance targeting revenue growth and double-digit earnings growth, expecting improved demand later in the year, particularly in biopharma and industrial research.
